{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:00:23Z","timestamp":1794898823415,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Currently, strategies for improving alpha1 antitrypsin deficiency (AATD) diagnosis are needed. Here we report the performance of a multinational multiplex-based genotyping test on dried blood spots and buccal swabs sent by post or courier and with web registration for subjects with suspected AATD in Argentina, Brazil, Chile, Colombia, Spain, and Turkey.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was an observational, cross-sectional analysis of samples from patients with suspected AATD from March 2018 to January 2022. Samples were coded on a web platform and sent by post or courier to the central laboratory in Northern Spain. Allele-specific genotyping for the 14 most common mutations was carried out with the A1AT Genotyping Test (Progenika-Grifols, Spain). SERPINA1 gene sequencing was performed if none of the mutations were found or one variant was detected in heterozygous status and the AAT serum level was\u2009&lt;\u200960\u00a0mg\/dl, or if requested by the clinician in charge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 30,827 samples: 30,458 (94.7%) with final results after direct genotyping and 369 (1.1%) with additional gene sequencing. Only 0.3% of the samples were not processed due to their poor quality. The prevalence of the most frequent allele combinations was MS 14.7%, MZ 8.6%, SS 1.9%, SZ 1.9%, and ZZ 0.9%. Additionally, 70 cases with new mutations were identified. Family screening was conducted in 2.5% of the samples. Samples from patients with respiratory diseases other than COPD, including poorly controlled asthma or bronchiectasis, also presented AATD mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results confirm the viability of this diagnostic system for genotyping AATD conducted simultaneously in different countries. The system has proved satisfactory and can improve the timely diagnosis of AATD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02074-x","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:25:14Z","timestamp":1654849514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jos\u00e9 Luis","family":"Lopez-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Osaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Czischke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Fernandez Acquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"G\u00fcnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Rapun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Drobnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"6","key":"2074_CR1","doi-asserted-by":"publisher","first-page":"2001441","DOI":"10.1183\/13993003.01441-2020","volume":"56","author":"T Nakanishi","year":"2020","unstructured":"Nakanishi T, Forgetta V, Handa T, Hirai T, Mooser V, Lathrop GM, Cookson W, Richards JB. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur Respir J. 2020;56(6):2001441.","journal-title":"Eur Respir J"},{"issue":"4","key":"2074_CR2","doi-asserted-by":"publisher","first-page":"2000958","DOI":"10.1183\/13993003.00958-2020","volume":"56","author":"N Gupta","year":"2020","unstructured":"Gupta N, Gaudreault N, Theriault S, Li PZ, Henry C, Kirby M, Maltais F, Tan W, Bourbeau J, Bosse Y, et al. Granularity of SERPINA1 alleles by DNA sequencing in CanCOLD. Eur Respir J. 2020;56(4):2000958.","journal-title":"Eur Respir J"},{"issue":"2","key":"2074_CR3","first-page":"190","volume":"8","author":"S Gurevich","year":"2021","unstructured":"Gurevich S, Daya A, Da Silva C, Girard C, Rahaghi F. Improving screening for alpha-1 antitrypsin deficiency with direct testing in the pulmonary function testing laboratory. Chronic Obstr Pulm Dis (Miami, Fla). 2021;8(2):190\u20137.","journal-title":"Chronic Obstr Pulm Dis (Miami, Fla)"},{"issue":"9","key":"2074_CR4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.arbres.2019.11.010","volume":"56","author":"G Menga","year":"2020","unstructured":"Menga G, Fernandez Acquier M, Echazarreta AL, Sorroche PB, Lorenzon MV, Fernandez ME, Saez MS, grupo de estudio DA. Prevalence of alpha-1 antitrypsin deficiency in COPD patients in Argentina. The DAAT.AR Study. Arch Bronconeumol. 2020;56(9):571\u20137.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"2074_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.arbr.2020.04.010","volume":"57","author":"JL Lopez-Campos","year":"2021","unstructured":"Lopez-Campos JL, Casas-Maldonado F, Torres-Duran M, Medina-Gonzalvez A, Rodriguez-Fidalgo ML, Carrascosa I, Calle M, Osaba L, Rapun N, Drobnic E, et al. Results of a diagnostic procedure based on multiplex technology on dried blood spots and buccal swabs for subjects with suspected alpha1 antitrypsin deficiency. Arch Bronconeumol (Engl Ed). 2021;57(1):42\u201350.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"2","key":"2074_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.arbres.2019.09.009","volume":"56","author":"JL Lopez-Campos","year":"2020","unstructured":"Lopez-Campos JL, Carrasco Hernandez L, Marquez-Martin E, Ortega Ruiz F, Martinez Delgado B. Diagnostic performance of a lateral flow assay for the detection of alpha-1-antitrypsin deficiency. Arch Bronconeumol. 2020;56(2):124\u20136.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"2074_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arbres.2019.06.010","volume":"56","author":"P Ellis","year":"2020","unstructured":"Ellis P, Turner A. What do alpha-1 antitrypsin levels tell us about chronic inflammation in COPD? Arch Bronconeumol. 2020;56(2):72\u20133.","journal-title":"Arch Bronconeumol"},{"issue":"2","key":"2074_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.arbres.2019.03.001","volume":"56","author":"S Janciauskiene","year":"2020","unstructured":"Janciauskiene S, DeLuca DS, Barrecheguren M, Welte T, Miravitlles M. Serum levels of alpha1-antitrypsin and their relationship with COPD in the general Spanish population. Arch Bronconeumol. 2020;56(2):76\u201383.","journal-title":"Arch Bronconeumol"},{"key":"2074_CR9","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2147\/COPD.S224221","volume":"14","author":"M Veith","year":"2019","unstructured":"Veith M, Klemmer A, Anton I, El Hamss R, Rapun N, Janciauskiene S, Kotke V, Herr C, Bals R, Vogelmeier CF, et al. Diagnosing alpha-1-antitrypsin deficiency using a PCR\/luminescence-based technology. Int J Chron Obstruct Pulmon Dis. 2019;14:2535\u201342.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"2074_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23279","volume":"34","author":"S Ottaviani","year":"2020","unstructured":"Ottaviani S, Barzon V, Buxens A, Gorrini M, Larruskain A, El Hamss R, Balderacchi AM, Corsico AG, Ferrarotti I. Molecular diagnosis of alpha1-antitrypsin deficiency: a new method based on Luminex technology. J Clin Lab Anal. 2020;34(7): e23279.","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"2074_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.arbr.2020.02.007","volume":"57","author":"M Barrecheguren","year":"2021","unstructured":"Barrecheguren M, Torres-Duran M, Casas-Maldonado F, Miravitlles M. Spanish implementation of the new international alpha-1 anitrypsin deficiency international registry: the European Alpha-1 Research Collaboration (EARCO). Arch Bronconeumol (Engl Ed). 2021;57(2):81\u20132.","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"2","key":"2074_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.chest.2021.09.041","volume":"161","author":"JR Ashenhurst","year":"2022","unstructured":"Ashenhurst JR, Nhan H, Shelton JF, Wu S, Tung JY, Elson SL, Stoller JK, Me Research T. Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report. Chest. 2022;161(2):373\u201381.","journal-title":"Chest"},{"issue":"5","key":"2074_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1753465812457113","volume":"6","author":"FJ de Serres","year":"2012","unstructured":"de Serres FJ, Blanco I. Prevalence of alpha1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277\u201395.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"2074_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1183\/09031936.06.00062305","volume":"27","author":"I Blanco","year":"2006","unstructured":"Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27(1):77\u201384.","journal-title":"Eur Respir J"},{"issue":"4","key":"2074_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1183\/09031936.05.00007305","volume":"26","author":"C de la Roza","year":"2005","unstructured":"de la Roza C, Rodriguez-Frias F, Lara B, Vidal R, Jardi R, Miravitlles M. Results of a case-detection programme for alpha1-antitrypsin deficiency in COPD patients. Eur Respir J. 2005;26(4):616\u201322.","journal-title":"Eur Respir J"},{"issue":"1","key":"2074_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/15412555.2017.1414779","volume":"15","author":"L Meira","year":"2018","unstructured":"Meira L, Boaventura R, Seixas S, Sucena M. Alpha-1 antitrypsin deficiency detection in a Portuguese population. COPD. 2018;15(1):4\u20139.","journal-title":"COPD"},{"key":"2074_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/TACG.S257511","volume":"14","author":"S Seixas","year":"2021","unstructured":"Seixas S, Marques PI. Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. Appl Clin Genet. 2021;14:173\u201394.","journal-title":"Appl Clin Genet"},{"issue":"135","key":"2074_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1183\/09059180.00010614","volume":"24","author":"J Chorostowska-Wynimko","year":"2015","unstructured":"Chorostowska-Wynimko J. Targeted screening programmes in COPD: how to identify individuals with alpha1-antitrypsin deficiency. Eur Respir Rev. 2015;24(135):40\u20135.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2074_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-016-0453-8","volume":"11","author":"T Greulich","year":"2016","unstructured":"Greulich T, Nell C, Herr C, Vogelmeier C, Kotke V, Wiedmann S, Wencker M, Bals R, Koczulla AR. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003\u20132015. Orphanet J Rare Dis. 2016;11(1):75.","journal-title":"Orphanet J Rare Dis"},{"key":"2074_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1465-9921-12-91","volume":"12","author":"TP Carroll","year":"2011","unstructured":"Carroll TP, O\u2019Connor CA, Floyd O, McPartlin J, Kelleher DP, O\u2019Brien G, Dimitrov BD, Morris VB, Taggart CC, McElvaney NG. The prevalence of alpha-1 antitrypsin deficiency in Ireland. Respir Res. 2011;12:91.","journal-title":"Respir Res"},{"issue":"6","key":"2074_CR21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1157\/13089541","volume":"42","author":"C de la Roza","year":"2006","unstructured":"de la Roza C, Lara B, Vila S, Miravitlles M. Alpha1-antitrypsin deficiency: situation in Spain and development of a screening program. Arch Bronconeumol. 2006;42(6):290\u20138.","journal-title":"Arch Bronconeumol"},{"issue":"5","key":"2074_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1164\/ajrccm\/142.5.1185","volume":"142","author":"MD Holmes","year":"1990","unstructured":"Holmes MD, Brantly ML, Crystal RG. Molecular analysis of the heterogeneity among the P-family of alpha-1-antitrypsin alleles. Am Rev Respir Dis. 1990;142(5):1185\u201392.","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"2074_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF02591409","volume":"22","author":"M Seri","year":"1992","unstructured":"Seri M, Magi B, Cellesi C, Olia PM, Renieri A, De Marchi M. Molecular characterization of the P and I variants of alpha 1-antitrypsin. Int J Clin Lab Res. 1992;22(2):119\u201321.","journal-title":"Int J Clin Lab Res"},{"key":"2074_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13601-018-0231-x","volume":"8","author":"I Suarez-Lorenzo","year":"2018","unstructured":"Suarez-Lorenzo I, de Castro FR, Cruz-Niesvaara D, Herrera-Ramos E, Rodriguez-Gallego C, Carrillo-Diaz T. Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites. Clin Transl Allergy. 2018;8:44.","journal-title":"Clin Transl Allergy"},{"key":"2074_CR25","doi-asserted-by":"crossref","unstructured":"Suarez-Lorenzo I, Hernandez-Brito E, Almeida-Quintana L, Llanos CG, Gonzalez-Quevedo N, Carrillo-Diaz T, Rodriguez-Gallego C. Alpha-1 antitrypsin deficiency hidden in allegedly normal variants. J Asthma. 2021:1\u20134.","DOI":"10.1080\/02770903.2021.1944186"},{"key":"2074_CR26","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.2147\/COPD.S271810","volume":"15","author":"M Veith","year":"2020","unstructured":"Veith M, Tuffers J, Peychev E, Klemmer A, Kotke V, Janciauskiene S, Wilhelm S, Bals R, Koczulla AR, Vogelmeier CF, et al. The distribution of alpha-1 antitrypsin genotypes between patients with COPD\/emphysema, asthma and bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2020;15:2827\u201336.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"7","key":"2074_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/thoraxjnl-2019-214195","volume":"75","author":"L Carreto","year":"2020","unstructured":"Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, Wilson R, Furrie E, Loebinger M, Chalmers JD. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax. 2020;75(7):592\u20133.","journal-title":"Thorax"},{"issue":"3","key":"2074_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/rmed.2001.1237","volume":"96","author":"M Miravitlles","year":"2002","unstructured":"Miravitlles M, Vila S, Torrella M, Balcells E, Rodriguez-Frias F, de la Roza C, Jardi R, Vidal R. Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir Med. 2002;96(3):186\u201392.","journal-title":"Respir Med"},{"issue":"9","key":"2074_CR29","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.rmed.2006.01.009","volume":"100","author":"IH van Veen","year":"2006","unstructured":"van Veen IH, ten Brinke A, van der Linden AC, Rabe KF, Bel EH. Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. Respir Med. 2006;100(9):1534\u20139.","journal-title":"Respir Med"},{"issue":"2","key":"2074_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1098-1004(200102)17:2<155::AID-HUMU17>3.0.CO;2-6","volume":"17","author":"V Pillay","year":"2001","unstructured":"Pillay V, Halsall DJ, Gaillard C, Lomas DA, Mahadeva R. A novel polymorphism (471C\u2013>T) in alpha-1-antitrypsin in a patient with asthma. Hum Mutat. 2001;17(2):155\u20136.","journal-title":"Hum Mutat"},{"issue":"2","key":"2074_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/1098-1004(200102)17:2<156::AID-HUMU19>3.0.CO;2-Y","volume":"17","author":"R Mahadeva","year":"2001","unstructured":"Mahadeva R, Gaillard M, Pillay V, Halkas A, Lomas D. Characterization of a new variant of alpha(1)-antitrypsin E(Johannesburg) (H15N) in association with asthma. Hum Mutat. 2001;17(2):156.","journal-title":"Hum Mutat"},{"issue":"5","key":"2074_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00408-017-0033-2","volume":"195","author":"GE Carpagnano","year":"2017","unstructured":"Carpagnano GE, Santacroce R, Palmiotti GA, Leccese A, Giuffreda E, Margaglione M, Foschino Barbaro MP, Aliberti S, Lacedonia D. A new SERPINA-1 missense mutation associated with alpha-1 antitrypsin deficiency and bronchiectasis. Lung. 2017;195(5):679\u201382.","journal-title":"Lung"},{"key":"2074_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2147\/COPD.S80173","volume":"10","author":"K Milger","year":"2015","unstructured":"Milger K, Holdt LM, Teupser D, Huber RM, Behr J, Kneidinger N. Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. Int J Chron Obstruct Pulmon Dis. 2015;10:891\u20137.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"2074_CR34","first-page":"145","volume":"6","author":"E Eden","year":"2019","unstructured":"Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, Daniels MLA, DiMango A, Fennelly K, Griffith DE, et al. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia-results from the U.S. bronchiectasis research registry. Chronic Obstr Pulm Dis (Miami, Fla). 2019;6(2):145\u201353.","journal-title":"Chronic Obstr Pulm Dis (Miami, Fla)"},{"key":"2074_CR35","doi-asserted-by":"crossref","unstructured":"Aggarwal N, Delgado BM, Salipalli S, Matamala N, Rademacher J, Schwerk N, Welte T, Janciauskiene S, Ringshausen FC. Why do some adults with PiMZ alpha1-antitrypsin develop bronchiectasis? [corrected]. ERJ Open Res. 2016; 2(2).","DOI":"10.1183\/23120541.00021-2016"},{"issue":"5","key":"2074_CR36","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jaip.2017.01.008","volume":"5","author":"T Kelbel","year":"2017","unstructured":"Kelbel T, Morris D, Walker D, Henao MP, Craig T. The Allergist\u2019s role in detection of severe alpha-1 antitrypsin deficiency. J Allergy Clin Immunol Pract. 2017;5(5):1302\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"2074_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.arbr.2017.07.013","volume":"54","author":"MA Martinez-Garcia","year":"2018","unstructured":"Martinez-Garcia MA, Maiz L, Olveira C, Giron RM, de la Rosa D, Blanco M, Canton R, Vendrell M, Polverino E, de Gracia J, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol (Engl Ed). 2018;54(2):79\u201387.","journal-title":"Arch Bronconeumol (Engl Ed)"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02074-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T08:27:51Z","timestamp":1654849671000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2074"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02074-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study reports the results of a diagnostic procedure that is approved for use in all the participating countries and, therefore, constitutes standard clinical practice. Consequently, since it is not an experimental procedure, approval by an ethics committee was not considered necessary. All patients included signed a written informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JLLC has received honoraria during the last three years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Laboratorios Esteve, Laboratorios Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Menarini, Novartis, Rovi, and Teva. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Inhibrx, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols and research grants from Grifols. AA has received speaker fees from Astra Zeneca, Boehringer Ingelheim, Chiesi (Amarey), Cipla, Zambon, and Novartis, consulting fees from Sanofi, GlaxoSmithKline, Glenmark and research grants from Grifols, Boehringer Ingelheim and Astra Zeneca. HG has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): Abdi\u0130brahim, AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Dem Pharma, Deva, Eczac\u0131ba\u015f\u0131, Exeltis, GlaxoSmithCline, Grifols, ILKO, NeuTec, Nobel, Novartis, Pfizer, Pharmactive, Recordati, Roche, Sandoz and VEM. MFA has received honoraria during the last five years for lecturing, scientific advice, participation in clinical studies or writing for publications for: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis and Tuteur.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}